{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:56:35Z","timestamp":1792684595724,"version":"4.5.0"},"reference-count":160,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ackdjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1053\/j.ackd.2019.08.006","type":"journal-article","created":{"date-parts":[[2020,3,5]],"date-time":"2020-03-05T19:14:31Z","timestamp":1583435671000},"page":"56-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":237,"title":["The Many Faces of Calcineurin Inhibitor Toxicity\u2014What the FK?"],"prefix":"10.1053","volume":"27","author":[{"given":"Samira S.","family":"Farouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Rein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1053\/j.ackd.2019.08.006_bib1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ajt.15274","article-title":"OPTN\/SRTR 2017 annual data report: kidney","volume":"19","author":"Hart","year":"2019","journal-title":"Am J Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2215\/CJN.07110615","article-title":"Treatment with glucocorticoids or calcineurin inhibitors in primary FSGS","volume":"11","author":"Laurin","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12882-017-0467-z","article-title":"Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis","volume":"18","author":"Song","year":"2017","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib4","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.kint.2018.08.025","article-title":"A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis","volume":"95","author":"Rovin","year":"2019","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib5","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1046\/j.1523-1755.2001.0590041484.x","article-title":"Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial","volume":"59","author":"Cattran","year":"2001","journal-title":"Kidney Int"},{"issue":"24","key":"10.1053\/j.ackd.2019.08.006_bib6","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib7","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/BF01973261","article-title":"Biological effects of cyclosporin A: a new antilymphocytic agent","volume":"6","author":"Borel","year":"1976","journal-title":"Agents Actions"},{"issue":"8151","key":"10.1053\/j.ackd.2019.08.006_bib8","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(79)92440-1","article-title":"Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers","volume":"2","author":"Calne","year":"1979","journal-title":"Lancet"},{"issue":"8670","key":"10.1053\/j.ackd.2019.08.006_bib9","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(89)91014-3","article-title":"FK 506 for liver, kidney, and pancreas transplantation","volume":"2","author":"Starzl","year":"1989","journal-title":"Lancet"},{"issue":"6338","key":"10.1053\/j.ackd.2019.08.006_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/352803a0","article-title":"Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A","volume":"352","author":"Flanagan","year":"1991","journal-title":"Nature"},{"issue":"6380","key":"10.1053\/j.ackd.2019.08.006_bib11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/357695a0","article-title":"Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation","volume":"357","author":"Clipstone","year":"1992","journal-title":"Nature"},{"issue":"6380","key":"10.1053\/j.ackd.2019.08.006_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/357692a0","article-title":"FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin","volume":"357","author":"O'Keefe","year":"1992","journal-title":"Nature"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.2215\/CJN.01531005","article-title":"Large within-day variation in cyclosporine absorption: circadian variation or food effect?","volume":"1","author":"Curtis","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2019.08.006_bib14","unstructured":"Full Prescribing Information for Prograf. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210115s000,050708s047,050709s040lbl.pdf. Accessed September 7, 2019."},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1067\/mcp.2001.113183","article-title":"The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups","volume":"69","author":"Mancinelli","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.arcmed.2012.05.005","article-title":"CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing","volume":"43","author":"Garcia-Roca","year":"2012","journal-title":"Arch Med Res"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/TP.0b013e318200e991","article-title":"Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium","volume":"91","author":"Jacobson","year":"2011","journal-title":"Transplantation"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/ajt.13495","article-title":"Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles","volume":"16","author":"Oetting","year":"2016","journal-title":"Am J Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib19","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FTD.0b013e3181e06818","article-title":"Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients","volume":"32","author":"Kuypers","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/jhg.2015.12","article-title":"The donor ABCB1 (MDR-1) C3435T polymorphism is a determinant of the graft glomerular filtration rate among tacrolimus treated kidney transplanted patients","volume":"60","author":"Tavira","year":"2015","journal-title":"J Hum Genet"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib21","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2215\/CJN.03791106","article-title":"Therapeutic monitoring of calcineurin inhibitors for the nephrologist","volume":"2","author":"Schiff","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2125.1999.00007.x","article-title":"Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients","volume":"48","author":"Bottiger","year":"1999","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.006_bib23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/tri.12155","article-title":"Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF genomics","volume":"26","author":"Israni","year":"2013","journal-title":"Transpl Int"},{"issue":"8505","key":"10.1053\/j.ackd.2019.08.006_bib24","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(86)90355-7","article-title":"Cyclosporin in therapeutic doses increases renal allograft vascular resistance","volume":"2","author":"Curtis","year":"1986","journal-title":"Lancet"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib25","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI116440","article-title":"Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles","volume":"91","author":"Lanese","year":"1993","journal-title":"J Clin Invest"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib26","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1172\/JCI116777","article-title":"Arginine feeding modifies cyclosporine nephrotoxicity in rats","volume":"92","author":"De Nicola","year":"1993","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib27","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1600-6143.2004.00428.x","article-title":"Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination","volume":"4","author":"Fortin","year":"2004","journal-title":"Am J Transpl"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMoa052891","article-title":"Long-term outcome of renal transplantation from older donors","volume":"354","author":"Remuzzi","year":"2006","journal-title":"N Engl J Med"},{"issue":"8409","key":"10.1053\/j.ackd.2019.08.006_bib29","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(84)91166-8","article-title":"Interstitial fibrosis in renal allografts after 12 to 46 months of cyclosporin treatment: beneficial effect of low doses in early post-transplantation period","volume":"2","author":"Klintmalm","year":"1984","journal-title":"Lancet"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00007890-198509000-00008","article-title":"Pharmacokinetics and nephrotoxicity of cyclosporine in renal transplant recipients","volume":"40","author":"Henny","year":"1985","journal-title":"Transplantation"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.006_bib31","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/00007890-199610150-00005","article-title":"An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group","volume":"62","author":"Laskow","year":"1996","journal-title":"Transplantation"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib32","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000086569","article-title":"Tacrolimus and nonsteroidal anti-inflammatory drugs: an association to be avoided","volume":"25","author":"Soubhia","year":"2005","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib33","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.006_bib34","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/00007890-200212150-00002","article-title":"Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement","volume":"74","author":"Macphee","year":"2002","journal-title":"Transplantation"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","article-title":"Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients","volume":"71","author":"Trofe-Clark","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.006_bib37","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1097\/01.ASN.0000073901.94759.36","article-title":"Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients","volume":"14","author":"Anglicheau","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.006_bib38","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.TP.0000090753.99170.89","article-title":"Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients","volume":"76","author":"Thervet","year":"2003","journal-title":"Transplantation"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.006_bib39","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.TP.0000137789.58694.B4","article-title":"Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients","volume":"78","author":"Tsuchiya","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib40","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1432-2277.2012.01446.x","article-title":"Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation","volume":"25","author":"Gervasini","year":"2012","journal-title":"Transpl Int"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib41","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0091270010370704","article-title":"Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?","volume":"51","author":"Singh","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.006_bib42","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1111\/ajt.13788","article-title":"Long-term clinical impact of adaptation of initial tacrolimus dosing to CYP3A5 genotype","volume":"16","author":"Pallet","year":"2016","journal-title":"Am J Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib43","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1016\/S0041-1345(98)00515-6","article-title":"Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits","volume":"30","author":"Del Moral","year":"1998","journal-title":"Transpl Proc"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib44","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1523-1755.2001.00782.x","article-title":"Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients","volume":"60","author":"Koziolek","year":"2001","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1399-3046.2005.00315.x","article-title":"Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein","volume":"9","author":"Maezono","year":"2005","journal-title":"Pediatr Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib46","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1600-6143.2012.04347.x","article-title":"Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011","volume":"13","author":"Ceschi","year":"2013","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.006_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13098","article-title":"Using known drug interactions to manage supratherapeutic calcineurin inhibitor concentrations","volume":"31","author":"Lange","year":"2017","journal-title":"Clin Transpl"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib48","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/MNH.0000000000000590","article-title":"The nephrologist's guide to cannabis and cannabinoids","volume":"29","author":"Rein","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib49","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3109\/03602532.2013.849268","article-title":"Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review","volume":"46","author":"Stout","year":"2014","journal-title":"Drug Metab Rev"},{"key":"10.1053\/j.ackd.2019.08.006_bib50","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.15398","article-title":"Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus [published online ahead of print April 23, 2019]","author":"Leino","year":"2019","journal-title":"Am J Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/00498259609046707","article-title":"Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes","volume":"26","author":"Jaeger","year":"1996","journal-title":"Xenobiotica"},{"key":"10.1053\/j.ackd.2019.08.006_bib52","doi-asserted-by":"crossref","first-page":"34845","DOI":"10.1038\/srep34845","article-title":"Bioprinting of 3D convoluted renal proximal tubules on perfusable chips","volume":"6","author":"Homan","year":"2016","journal-title":"Sci Rep"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.006_bib53","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1681\/ASN.V42214","article-title":"Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake","volume":"4","author":"Elzinga","year":"1993","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.006_bib55","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1021\/pr300260e","article-title":"Low-salt diet and cyclosporine nephrotoxicity: changes in kidney cell metabolism","volume":"11","author":"Klawitter","year":"2012","journal-title":"J Proteome Res"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib56","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1681\/ASN.V641186","article-title":"Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin","volume":"6","author":"Pichler","year":"1995","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib57","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/00007890-199402000-00001","article-title":"Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model","volume":"57","author":"Andoh","year":"1994","journal-title":"Transplantation"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib58","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/ki.1995.312","article-title":"Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity","volume":"48","author":"Young","year":"1995","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib59","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ki.1995.311","article-title":"Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy","volume":"48","author":"Young","year":"1995","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/01.TP.0000128612.75163.26","article-title":"Evolution and pathophysiology of renal-transplant glomerulosclerosis","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.TP.0000128636.70499.6E","article-title":"Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology","volume":"78","author":"Nankivell","year":"2004","journal-title":"Transplantation"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib62","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1038\/ki.1996.480","article-title":"Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy","volume":"50","author":"Bakris","year":"1996","journal-title":"Kidney Int"},{"issue":"suppl 68","key":"10.1053\/j.ackd.2019.08.006_bib63","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1046\/j.1523-1755.1998.06826.x","article-title":"Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin","volume":"54","author":"Martinez-Castelao","year":"1998","journal-title":"Kidney Int Suppl"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.006_bib64","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/00004872-200018080-00017","article-title":"Dihydropyridine calcium antagonists and renal function in hypertensive kidney transplant recipients","volume":"18","author":"Rump","year":"2000","journal-title":"J Hypertens"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib65","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/ki.1993.101","article-title":"Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion","volume":"43","author":"Ruggenenti","year":"1993","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/ki.1993.61","article-title":"Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants","volume":"43","author":"Mourad","year":"1993","journal-title":"Kidney Int"},{"issue":"4 Pt 2","key":"10.1053\/j.ackd.2019.08.006_bib67","first-page":"F491","article-title":"Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril","volume":"269","author":"Burdmann","year":"1995","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib68","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1046\/j.1523-1755.1999.00597.x","article-title":"Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy","volume":"56","author":"Campistol","year":"1999","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib69","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","article-title":"Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials","volume":"69","author":"Hiremath","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.006_bib70","doi-asserted-by":"crossref","first-page":"e103660","DOI":"10.1371\/journal.pone.0103660","article-title":"Predictive usefulness of urinary biomarkers for the identification of cyclosporine A-induced nephrotoxicity in a rat model","volume":"9","author":"Carlos","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.006_bib71","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1111\/ajt.13322","article-title":"Safe conversion from tacrolimus to belatacept in high immunologic risk kidney transplant recipients with allograft dysfunction","volume":"15","author":"Gupta","year":"2015","journal-title":"Am J Transpl"},{"key":"10.1053\/j.ackd.2019.08.006_bib72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fmed.2018.00261","article-title":"Electrolyte and acid-base disorders in the renal transplant recipient","volume":"5","author":"Pochineni","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib73","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1093\/ndt\/gfg515","article-title":"Hyponatraemia and hyperkalaemia are more frequent in renal transplant recipients treated with tacrolimus than with cyclosporin. Further evidence for differences between cyclosporin and tacrolimus nephrotoxicities","volume":"19","author":"Higgins","year":"2004","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/archinte.1985.00360030153026","article-title":"Effects of cyclosporine on the renin-angiotensin-aldosterone system and potassium excretion in renal transplant recipients","volume":"145","author":"Bantle","year":"1985","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.006_bib75","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.V281279","article-title":"Studies to determine the basis for hyperkalemia in recipients of a renal transplant who are treated with cyclosporine","volume":"2","author":"Kamel","year":"1992","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib76","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cmet.2014.12.006","article-title":"Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride","volume":"21","author":"Terker","year":"2015","journal-title":"Cell Metab"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib77","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/ki.1993.339","article-title":"Cyclosporin A inhibits apical secretory K+ channels in rabbit cortical collecting tubule principal cells","volume":"44","author":"Ling","year":"1993","journal-title":"Kidney Int"},{"issue":"8346","key":"10.1053\/j.ackd.2019.08.006_bib78","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0140-6736(83)90345-8","article-title":"Hyperkalemia in cyclosporin-treated renal allograft recipients","volume":"2","author":"Adu","year":"1983","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib79","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1046\/j.1399-0012.2003.00154.x","article-title":"Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression","volume":"18","author":"Heering","year":"2004","journal-title":"Clin Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib80","first-page":"245","article-title":"Hyperchloremic metabolic acidosis with high serum potassium in renal transplant recipients: a cyclosporine A associated side effect","volume":"25","author":"Stahl","year":"1986","journal-title":"Clin Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib81","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000183479","article-title":"Serum potassium concentrations in cyclosporine- and azathioprine-treated renal transplant patients","volume":"40","author":"Foley","year":"1985","journal-title":"Nephron"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.006_bib82","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1073\/pnas.1817281116","article-title":"Calcineurin dephosphorylates Kelch-like 3, reversing phosphorylation by angiotensin II and regulating renal electrolyte handling","volume":"116","author":"Ishizawa","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1053\/j.ackd.2019.08.006_bib83","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1073\/pnas.1421441112","article-title":"KLHL3 regulates paracellular chloride transport in the kidney by ubiquitination of claudin-8","volume":"112","author":"Gong","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.ackd.2019.08.006_bib84","first-page":"586859","article-title":"Fludrocortisone therapy in renal transplant recipients with persistent hyperkalemia","volume":"2012","author":"Marfo","year":"2012","journal-title":"Case Rep Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib85","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/1319-2442.124539","article-title":"Role of fludrocortisone in the management of tacrolimus-induced hyperkalemia in a renal transplant recipient","volume":"25","author":"Sivakumar","year":"2014","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib86","first-page":"479","article-title":"Cyclosporine nephrotoxicity and early posttransplant hyperkalemia in living-donor renal recipients: report of 4 cases","volume":"12","author":"Pavleska-Kuzmanovska","year":"2014","journal-title":"Exp Clin Transpl"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib87","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/jcpt.12485","article-title":"Clinical analysis of hyperkalemic renal tubular acidosis caused by calcineurin inhibitors in solid organ transplant recipients","volume":"42","author":"Lin","year":"2017","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.006_bib88","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00467-014-2842-3","article-title":"Fludrocortisone as a new tool for managing tubulopathy after pediatric renal transplantation: a series of cases","volume":"29","author":"Bacchetta","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/petr.13134","article-title":"Fludrocortisone\u2014a treatment for tubulopathy post-paediatric renal transplantation: a national paediatric nephrology unit experience","volume":"22","author":"Ali","year":"2018","journal-title":"Pediatr Transpl"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.006_bib90","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1016\/j.transproceed.2011.07.006","article-title":"Fludrocortisone is effective in the management of tacrolimus-induced hyperkalemia in liver transplant recipients","volume":"43","author":"Dick","year":"2011","journal-title":"Transpl Proc"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib91","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1681\/ASN.2016070793","article-title":"Metabolic acidosis and long-term clinical outcomes in kidney transplant recipients","volume":"28","author":"Park","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib92","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.ajkd.2018.12.023","article-title":"Metabolic acidosis 1 year following kidney transplantation and subsequent cardiovascular events and mortality: an observational cohort study","volume":"73","author":"Djamali","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib93","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/ki.1994.317","article-title":"Evidence that the inhibition of Na+\/K(+)-ATPase activity by FK506 involves calcineurin","volume":"46","author":"Lea","year":"1994","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ki.1993.38","article-title":"Nephron segment-specific inhibition of Na+\/K(+)-ATPase activity by cyclosporin A","volume":"43","author":"Tumlin","year":"1993","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib95","doi-asserted-by":"crossref","first-page":"F40","DOI":"10.1152\/ajprenal.00218.2004","article-title":"Cyclosporin A produces distal renal tubular acidosis by blocking peptidyl prolyl cis-trans isomerase activity of cyclophilin","volume":"288","author":"Watanabe","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib96","doi-asserted-by":"crossref","first-page":"F587","DOI":"10.1152\/ajprenal.00130.2018","article-title":"\u201cI don't get no respect\u201d: the role of chloride in acute kidney injury","volume":"316","author":"Rein","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.006_bib97","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1681\/ASN.2008111205","article-title":"Bicarbonate supplementation slows progression of CKD and improves nutritional status","volume":"20","author":"de Brito-Ashurst","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib98","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12882-018-0956-8","article-title":"Preservation of kidney function in kidney transplant recipients by alkali therapy (Preserve-Transplant Study): rationale and study protocol","volume":"19","author":"Wiegand","year":"2018","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.006_bib99","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1399-3046.2007.00729.x","article-title":"Determinants of urinary calcium and uric acid excretion in children after renal transplantation","volume":"11","author":"Peterson","year":"2007","journal-title":"Pediatr Transpl"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib100","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s00467-005-1831-y","article-title":"Hypocitraturia as a risk factor for nephrocalcinosis after kidney transplantation","volume":"20","author":"Stapenhorst","year":"2005","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib101","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/01.ASN.0000113318.56023.B6","article-title":"Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia","volume":"15","author":"Nijenhuis","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib102","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1046\/j.1523-1755.2002.00670.x","article-title":"Cyclosporine A-induced hypercalciuria in calbindin-D28k knockout and wild-type mice","volume":"62","author":"Lee","year":"2002","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib103","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/0002-9343(87)90900-4","article-title":"Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine","volume":"83","author":"Barton","year":"1987","journal-title":"Am J Med"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib104","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/oxfordjournals.ndt.a092115","article-title":"Reduced erythrocyte and leukocyte magnesium is associated with cyclosporin treatment and hypertension in renal transplant patients","volume":"7","author":"al-Khursany","year":"1992","journal-title":"Nephrol Dial Transpl"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.006_bib105","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/ndt\/5.9.812","article-title":"Cyclosporin-induced renal magnesium leak in renal transplant patients","volume":"5","author":"Scoble","year":"1990","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib106","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3390\/nu10060729","article-title":"Serum magnesium after kidney transplantation: a systematic review","volume":"10","author":"Garnier","year":"2018","journal-title":"Nutrients"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib107","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3109\/07435800.2015.1094088","article-title":"Hypomagnesemia linked to new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis","volume":"41","author":"Cheungpasitporn","year":"2016","journal-title":"Endocr Res"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib108","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.transproceed.2017.01.070","article-title":"Serum magnesium and related factors in long-term renal transplant recipients: an observational study","volume":"49","author":"Rodrigues","year":"2017","journal-title":"Transpl Proc"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib109","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1042\/cs0750509","article-title":"Cyclosporin-induced hypomagnesaemia and renal magnesium wasting in rats","volume":"75","author":"Wong","year":"1988","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib110","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00007890-200202150-00005","article-title":"Role of hypomagnesemia in chronic cyclosporine nephropathy","volume":"73","author":"Miura","year":"2002","journal-title":"Transplantation"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib111","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0002-9610(88)80196-X","article-title":"Hyperuricemia after renal transplantation","volume":"156","author":"Gores","year":"1988","journal-title":"Am J Surg"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib112","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0272-6386(87)80103-8","article-title":"The incidence of gout in renal transplant recipients","volume":"10","author":"West","year":"1987","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib113","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0002-9343(92)90104-J","article-title":"Hyperuricemia and gout among heart transplant recipients receiving cyclosporine","volume":"92","author":"Burack","year":"1992","journal-title":"Am J Med"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib114","first-page":"1773","article-title":"Hyperuricemia and gout in renal allograft recipients","volume":"24","author":"Delaney","year":"1992","journal-title":"Transpl Proc"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJM198908033210504","article-title":"Cyclosporine-induced hyperuricemia and gout","volume":"321","author":"Lin","year":"1989","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib116","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/TP.0b013e318254391b","article-title":"Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival","volume":"94","author":"Numakura","year":"2012","journal-title":"Transplantation"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib117","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1159\/000330274","article-title":"Use of uric acid-lowering agents limits experimental cyclosporine nephropathy","volume":"120","author":"Mazali","year":"2012","journal-title":"Nephron Exp Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib118","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1159\/000495081","article-title":"Trends in the causes of death among kidney transplant recipients in the United States (1996-2014)","volume":"48","author":"Awan","year":"2018","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib119","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1053\/j.ajkd.2004.03.013","article-title":"Hypertension after kidney transplantation","volume":"43","author":"Kasiske","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib120","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1681\/ASN.2014080834","article-title":"Assessment and management of hypertension in transplant patients","volume":"26","author":"Weir","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib121","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5301\/jn.5000174","article-title":"Pathogenesis of calcineurin inhibitor-induced hypertension","volume":"25","author":"Hoorn","year":"2012","journal-title":"J Nephrol"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.006_bib122","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.2217\/pgs.14.87","article-title":"Calcineurin inhibitors and hypertension: a role for pharmacogenetics?","volume":"15","author":"Moes","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1053\/j.ackd.2019.08.006_bib123","first-page":"CD007893","article-title":"Effect of cyclosporine on blood pressure","volume":"1","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib124","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0002-9343(88)80331-0","article-title":"Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent","volume":"85","author":"Curtis","year":"1988","journal-title":"Am J Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ki.2009.418","article-title":"Inhibition of calcineurin phosphatase promotes exocytosis of renin from juxtaglomerular cells","volume":"77","author":"Madsen","year":"2010","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.006_bib126","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/nm.2497","article-title":"The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension","volume":"17","author":"Hoorn","year":"2011","journal-title":"Nat Med"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib127","doi-asserted-by":"crossref","first-page":"e0176220","DOI":"10.1371\/journal.pone.0176220","article-title":"NaCl cotransporter abundance in urinary vesicles is increased by calcineurin inhibitors\u00a0and predicts thiazide sensitivity","volume":"12","author":"Tutakhel","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib128","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2016.12.017","article-title":"Chlorthalidone versus amlodipine for hypertension in kidney transplant recipients treated with tacrolimus: a randomized crossover trial","volume":"69","author":"Moes","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib129","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1681\/ASN.2015040466","article-title":"Renal deletion of 12 kDa FK506-binding protein attenuates tacrolimus-induced hypertension","volume":"27","author":"Lazelle","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.006_bib130","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1365-2362.2011.02517.x","article-title":"Cyclosporine metabolic side effects: association with the WNK4 system","volume":"41","author":"Melnikov","year":"2011","journal-title":"Eur J Clin Invest"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib131","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/TP.0000000000000961","article-title":"Calcineurin-inhibition results in upregulation of local renin and subsequent vascular endothelial growth factor production in renal collecting ducts","volume":"100","author":"Prokai","year":"2016","journal-title":"Transplantation"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.006_bib132","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1093\/ndt\/gfm390","article-title":"Ciclosporin-induced hypertension is associated with increased sodium transporter of the loop of Henle (NKCC2)","volume":"22","author":"Esteva-Font","year":"2007","journal-title":"Nephrol Dial Transpl"},{"issue":"3","key":"10.1053\/j.ackd.2019.08.006_bib133","doi-asserted-by":"crossref","first-page":"F489","DOI":"10.1152\/ajprenal.00575.2016","article-title":"Calcineurin inhibitor cyclosporine A activates renal Na-K-Cl cotransporters via local and systemic mechanisms","volume":"312","author":"Blankenstein","year":"2017","journal-title":"Am J Physiol Ren Physiol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib134","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1681\/ASN.2014070728","article-title":"Calcineurin and sorting-related receptor with A-type repeats interact to regulate the renal Na(+)-K(+)-2Cl(-) cotransporter","volume":"27","author":"Borschewski","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib135","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11892-009-0047-0","article-title":"Dyslipidemia following kidney transplantation: diagnosis and treatment","volume":"9","author":"Badiou","year":"2009","journal-title":"Curr Diab Rep"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib136","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.transproceed.2006.10.210","article-title":"Lipid profile during azathioprine or mycophenolate mofetil combinations with cyclosporine and steroids","volume":"39","author":"Akman","year":"2007","journal-title":"Transpl Proc"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib137","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/j.1742-7843.2007.00066.x","article-title":"Compared effect of immunosuppressive drugs cyclosporine A and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase","volume":"100","author":"Gueguen","year":"2007","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib138","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1001\/jama.1989.03430010065032","article-title":"Effects of cyclosporine therapy on plasma lipoprotein levels","volume":"262","author":"Ballantyne","year":"1989","journal-title":"JAMA"},{"issue":"10","key":"10.1053\/j.ackd.2019.08.006_bib139","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0025-6196(12)64916-7","article-title":"Cyclosporine, low-density lipoprotein, and cholesterol","volume":"63","author":"de Groen","year":"1988","journal-title":"Mayo Clin Proc"},{"issue":"1-2","key":"10.1053\/j.ackd.2019.08.006_bib140","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijpharm.2008.03.026","article-title":"Cyclosporine A and Rapamycin induce in\u00a0vitro cholesteryl ester transfer protein activity, and suppress lipoprotein lipase activity in human plasma","volume":"358","author":"Tory","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1053\/j.ackd.2019.08.006_bib141","first-page":"259","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney Inter Suppl"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.006_bib142","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/j.1600-6143.2012.04084.x","article-title":"Dyslipidemia and its therapeutic challenges in renal transplantation","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transpl"},{"key":"10.1053\/j.ackd.2019.08.006_bib143","unstructured":"Smith MEB, Lee NJ, Haney E, et al. Drug Class Review: HMGCoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5. Portland, OR: Oregon Health & Science University; November 2009. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK47273\/. Accessed September 7, 2019."},{"key":"10.1053\/j.ackd.2019.08.006_bib144","first-page":"CD003961","article-title":"Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients","volume":"4","author":"Webster","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib145","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2337\/dc11-1230","article-title":"New-onset diabetes after renal transplantation: risk assessment and management","volume":"35","author":"Ghisdal","year":"2012","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ackd.2019.08.006_bib146","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1111\/j.1600-6143.2009.02752.x","article-title":"Posttransplantation hypomagnesemia and its relation with immunosuppression as predictors of new-onset diabetes after transplantation","volume":"9","author":"Van Laecke","year":"2009","journal-title":"Am J Transpl"},{"issue":"7109","key":"10.1053\/j.ackd.2019.08.006_bib147","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature05097","article-title":"Calcineurin\/NFAT signalling regulates pancreatic beta-cell growth and function","volume":"443","author":"Heit","year":"2006","journal-title":"Nature"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.006_bib148","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/00007890-199506000-00018","article-title":"Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell","volume":"59","author":"Tamura","year":"1995","journal-title":"Transplantation"},{"issue":"4","key":"10.1053\/j.ackd.2019.08.006_bib149","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1681\/ASN.2011080835","article-title":"Early basal insulin therapy decreases new-onset diabetes after renal transplantation","volume":"23","author":"Hecking","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2019.08.006_bib150","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/00007890-199704150-00013","article-title":"A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group","volume":"63","author":"Pirsch","year":"1997","journal-title":"Transplantation"},{"issue":"5","key":"10.1053\/j.ackd.2019.08.006_bib151","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1432-2277.2000.tb01004.x","article-title":"Neurotoxicity of calcineurin inhibitors: impact and clinical management","volume":"13","author":"Bechstein","year":"2000","journal-title":"Transpl Int"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib152","first-page":"170","article-title":"Neurotoxicity of immunosuppressive therapies in organ transplantation","volume":"8","author":"Anghel","year":"2013","journal-title":"Maedica (Buchar)"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.006_bib153","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/jlts.2001.27475","article-title":"Neurotoxicity of immunosuppressive drugs","volume":"7","author":"Wijdicks","year":"2001","journal-title":"Liver Transpl"},{"issue":"8","key":"10.1053\/j.ackd.2019.08.006_bib154","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopathy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archneurol.2007.46","article-title":"Clinical spectrum of reversible posterior leukoencephalopathy syndrome","volume":"65","author":"Lee","year":"2008","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib156","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1034\/j.1600-051x.2000.027002144.x","article-title":"Reduction in gingival overgrowth associated with conversion from cyclosporin A to tacrolimus","volume":"27","author":"James","year":"2000","journal-title":"J Clin Periodontol"},{"issue":"2","key":"10.1053\/j.ackd.2019.08.006_bib157","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4103\/0972-124X.113066","article-title":"Drug-induced gingival overgrowth: the nemesis of gingiva unravelled","volume":"17","author":"Bharti","year":"2013","journal-title":"J Indian Soc Periodontol"},{"issue":"6","key":"10.1053\/j.ackd.2019.08.006_bib158","doi-asserted-by":"crossref","first-page":"C1593","DOI":"10.1152\/ajpcell.00537.2002","article-title":"Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes","volume":"284","author":"Gafter-Gvili","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"10.1053\/j.ackd.2019.08.006_bib159","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000018184","article-title":"Partial response of severe alopecia areata to cyclosporine A","volume":"199","author":"Ferrando","year":"1999","journal-title":"Dermatology"},{"issue":"11","key":"10.1053\/j.ackd.2019.08.006_bib160","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1097\/01.tp.0000181195.67084.94","article-title":"Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients","volume":"80","author":"Tricot","year":"2005","journal-title":"Transplantation"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559519301466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:02:31Z","timestamp":1761548551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559519301466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":160,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1548559519301466"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2019.08.006","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Many Faces of Calcineurin Inhibitor Toxicity\u2014What the FK?","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2019.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}